Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Xencor, Inc. has an average consensus rating of "Moderate Buy" from eight analysts, with seven buy ratings and one sell rating, setting an average 12-month target price of $23.71.
• The company's stock price has significantly fluctuated, with recent target price reductions from several analysts: Royal Bank of Canada from $32.00 to $15.00, and Barclays from $22.00 to $6.00.
• Xencor reported earnings of ($0.41) EPS, exceeding estimates, with revenue increasing 82.4% year-over-year to $43.61 million.

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight brokerages that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $23.7143.

Several research analysts have commented on XNCR shares. Royal Bank Of Canada reduced their price objective on Xencor from $32.00 to $15.00 and set an "outperform" rating on the stock in a report on Thursday. Wedbush decreased their price objective on Xencor from $31.00 to $26.00 and set an "outperform" rating for the company in a report on Thursday, August 7th. Barclays reduced their price target on Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a report on Thursday, May 8th. Finally, Wells Fargo & Company cut their price objective on Xencor from $33.00 to $27.00 and set an "overweight" rating for the company in a research note on Thursday, August 7th.

Xencor Stock Down 0.9%

Shares of XNCR opened at $7.44 on Friday. The business has a 50-day simple moving average of $8.36 and a two-hundred day simple moving average of $10.28. The stock has a market cap of $530.62 million, a price-to-earnings ratio of -3.10 and a beta of 0.89. Xencor has a 52 week low of $6.92 and a 52 week high of $27.24.

Xencor (NASDAQ:XNCR - Get Free Report) last released its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.37. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%.The firm had revenue of $43.61 million during the quarter, compared to analysts' expectations of $22.59 million. During the same quarter last year, the business posted ($1.07) earnings per share. The firm's revenue was up 82.4% on a year-over-year basis. On average, equities analysts anticipate that Xencor will post -3.68 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Xencor news, Director Kurt A. Gustafson sold 2,993 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $9.22, for a total transaction of $27,595.46. Following the transaction, the director owned 20,183 shares of the company's stock, valued at approximately $186,087.26. This trade represents a 12.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ellen Feigal sold 2,993 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the transaction, the director directly owned 19,183 shares in the company, valued at approximately $176,867.26. The trade was a 13.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,194 shares of company stock worth $103,209 over the last ninety days. Corporate insiders own 4.76% of the company's stock.

Institutional Investors Weigh In On Xencor

A number of hedge funds have recently added to or reduced their stakes in XNCR. Sterling Capital Management LLC lifted its position in Xencor by 732.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 1,040 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Xencor during the 4th quarter worth approximately $34,000. State of Wyoming acquired a new position in shares of Xencor during the 1st quarter worth approximately $34,000. CWM LLC raised its position in shares of Xencor by 195.5% during the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company's stock worth $36,000 after purchasing an additional 2,231 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in Xencor by 118.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company's stock worth $44,000 after acquiring an additional 3,018 shares during the period.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.